06 September, 2017

Trans-Hit Biomarkers Inc. Announces the Appointment to its Scientific Advisory Board of Two Expert Pathologists in Immuno-Oncology

Trans-Hit Biomarkers, Inc., a leading human tissue procurement CRO with an extensive collection capability for biospecimens and clinical samples today announced the establishment of its scientific advisory board with the appointment of two board-certified pathologists who are well-known for their expertise in the biobanking and biomarker fields: Paul Hofman, (Director of the Biobank of Nice, France), and Michael Roehrl, (Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center, New York, USA).

Paul Hofman, M.D., Ph.D. is Professor of Pathology at the Nice Sophia Antipolis University, France. He did post-doc training in Pathology at the Brigham and Women’s Hospital (Harvard Medical School, USA) and at the Max Planck Institute (Tübingen, Germany). He is Director of the Biobank of Nice, Director of the Laboratory of Clinical and Experimental Pathology at the Nice Hospital (Nice, France), and Director of the Tumor Molecular Biology Unit at Pasteur Hospital Inserm U1081 that is aiming to decipher the mechanisms occurring during the cross talk between immune cells and cancer cells, especially in lung cancers.

Michael Roehrl M.D., Ph.D., is Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center, New York, USA. He is dually board-certified in Pathology and Laboratory Medicine. He holds an MD from the Technical University of Munich, a Ph.D. in Biological Chemistry from Harvard University, and trained clinically at Massachusetts General Hospital in Boston. Michael Roehrl was previously Director of the UHN Program in BioSpecimen Sciences and Associate Professor of Pathology and Laboratory Medicine at the University of Toronto. His main scientific expertise is related to the discovery and development of new molecular diagnostics for colorectal and pancreatic cancers.

Trans-Hit Bio intends to consult with the newly created SAB to explore new avenues to facilitate and accelerate access to the high-quality human biospecimens needed for biomarker development in immuno-oncology, especially the establishment of international consortia of biobanks. "We are thrilled to expand our internal scientific expertise with this SAB including these two expert pathologists and leading researchers in the field of immuno-oncology,” commented Dr. Pascal Puchois, CEO of Trans-Hit Biomarkers. "By drawing upon their deep expertise and experience of the effect that the quality of tissues has on biomarker and drug R&D, we will certainly bring to our clients a unique added scientific guidance.”